CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Acura Pharmaceuticals Inc. v. Par Pharmaceutical Inc.

1:12-cv-01372

Overview

Case Number 1:12-cv-01372
Filing Date 2012-10-31
Status Terminated
Termination Date 2013-11-13
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Par Pharmaceutical Inc. Operating Company

Represented By

8 Attorneys Listed

Taniel E. Anderson

Email: taniel.anderson@afslaw.com

Stephen Yang

Email: syang@steptoe.com

Richard J. Berman

Email: Richard.Berman@afslaw.com

Katharine Lester Mowery

Richards, Layton & Finger, PA

Tel: +1 (302) 651-7623

Richards, Layton & Finger, PA, One Rodney Square

Janine A. Carlan

Email: janine.carlan@afslaw.com

Jaclyn C. Levy

Friedlander & Gorris, P.A.

Tel: +1 (302) 984-6000
Fax: +1 (302) 658-1192

Friedlander & Gorris, P.A., 1201 N. Market Street

Aziz Burgy

Email: aburgy@axinn.com

Steven J. Fineman

Richards, Layton & Finger, PA

Tel: +1 (302) 658-6541

Richards, Layton & Finger, PA, One Rodney Square

Counter Defendant

Acura Pharmaceuticals Inc. Operating Company

Represented By

2 Attorneys Listed

Maryellen Noreika

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Jack B. Blumenfeld

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar 10 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts Counterparts in force
πŸ›οΈ
USPTO PTAB Trials Counterparts in force
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (10): πŸ‡ΊπŸ‡Έ US
Parallel Proceedings Across Jurisdictions (0 found):

No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.

Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

1 Patent

There is a single patent involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US7510726
Methods and compositions for deterring abuse of opioid containing dosage forms
Filed: 2007-03-09
Issued: 2009-03-31
Expiring Soon (109 days)
Expires: 2027-03-09

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Statutorily Barred

Narrowing Window β€” Imminent expiration makes injunctive relief unlikely to be granted.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term β€” No obviousness-type double patenting noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

7

Dispositive

0

Granted

0

Denied

0

Pending / Review

6

Motions by Category

Procedural / Extension Motion 3 Claim Construction / Markman Filing 4

Key Dispositive Motions & Rulings

Procedural / Extension Motion Pending / Under Review
STIPULATION TO EXTEND TIME for substantial completion of document production to November 1, 2013 - filed by Par Pharmaceutical Inc.. (Fineman, Steven) (Entered:...
Entry #63 • 2013-10-01 Document →
Claim Construction / Markman Filing Pending / Under Review
ORDER re (60 in 1:12-cv-01372-RGA, 63 in 1:12-cv-01371-RGA, 57 in 1:12-cv-01373-RGA) Stipulation and Order to Amend Scheduling Order, filed by Par Pharmaceutica...
Entry #61 • 2013-09-24 Document →
Claim Construction / Markman Filing Pending
SO ORDERED re (53 in 1:12-cv-01373-RGA, 56 in 1:12-cv-01372-RGA) Stipulation and Order amending the scheduling order, filed by Impax Laboratories Inc., Acura Ph...
Entry #57 • 2013-09-05 Document →
Claim Construction / Markman Filing Pending / Under Review
SO ORDERED re (53 in 1:12-cv-01373-RGA, 56 in 1:12-cv-01372-RGA) Stipulation and Order amending the scheduling order, filed by Impax Laboratories Inc., Acura Ph...
Entry #57 • 2013-09-05 Document →
Procedural / Extension Motion Pending / Under Review
STIPULATION TO EXTEND TIME to reach an Agreement on a Proposed Form of Protective Order to May 2, 2013 - filed by Par Pharmaceutical Inc.. (Fineman, Steven) (En...
Entry #24 • 2013-04-22 Document →
Claim Construction / Markman Filing Pending / Under Review
SCHEDULING ORDER: Case referred to the Magistrate Judge for the purpose of exploring ADR. Joinder of Parties due by 11/1/2013. Amended Pleadings due by 11/1/201...
Entry #21 • 2013-04-11 Document →

Docket Entries

(69 total)
Pleading / Complaint

COMPLAINT FOR PATENT INFRINGEMENT filed against Par Pharmaceutical Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 350, receipt number 311-1163851.) - filed by Acura Pharmaceuticals Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Civil Cover Sheet)(dmp, ) (Entered: 11/01/2012)

Entry #1 • 2012-10-31
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction (dmp, ) (Entered: 11/01/2012)

Entry #2 • 2012-10-31
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: On or about 9/21/2012. Date of Expiration of Patent: 03/16/2025.Thirty Month Stay Deadline: On or about 3/21/2015. (dmp, ) (Entered: 11/01/2012)

Entry #3 • 2012-10-31
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,510,726 B2;. (dmp, ) (Entered: 11/01/2012)

Entry #4 • 2012-10-31
1

Disclosure Statement pursuant to Rule 7.1 filed by Acura Pharmaceuticals Inc.. (dmp, ) (Entered: 11/01/2012)

Entry #5 • 2012-10-31
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc